HomeCASI • NASDAQ
CASI Pharmaceuticals Inc
Follow
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 13.36M | 94.30% |
Operating expense | 15.58M | 76.59% |
Net income | -14.37M | -137.32% |
Net profit margin | -107.59 | -22.14% |
Earnings per share | — | — |
EBITDA | -11.77M | -207.36% |
Effective tax rate | — | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 16.09M | -47.70% |
Total assets | 53.67M | -28.69% |
Total liabilities | 51.82M | 1.41% |
Total equity | 1.85M | — |
Shares outstanding | 15.49M | — |
Price to book | 17.42 | — |
Return on assets | -52.66% | — |
Return on capital | -108.44% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | -14.37M | -137.32% |
Cash from operations | — | — |
Cash from investing | — | — |
Cash from financing | — | — |
Net change in cash | — | — |
Free cash flow | — | — |
Previous close
$2.09
Day range
$2.01 - $2.05
Year range
$1.90 - $7.67
Market cap
31.14M USD
Avg Volume
9.72K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
About
Founded
1991
Headquarters
Website
Employees
233
